Insilico Medicine (3696.HK) saw a significant surge in early trading, with a nearly 10% increase, reaching a stock price of HK$52.4. Today, the company announced the publication of its latest joint research findings in Nature Biotechnology. Based on proteomic data from the Rentosertib Phase IIa clinical trial and evaluated by six proteomic aging clocks, the study found that participants treated with the drug exhibited a reduction in predicted biological age. Key lung function indicator FVC showed a significant dose-dependent reversal, aligning with the trend of age reversal. This study marks the first clinical evaluation of a potential 'first-in-class' drug candidate in the anti-aging field. Rentosertib is an innovative AI-driven drug with a molecular structure designed to target both disease and aging 'dual-effect targets'. The research also suggests that integrating aging biomarkers into standard clinical trials could accelerate the development of anti-aging and longevity therapies.